Circulation reports · 2026
Reperfusion Therapy and Outcomes in High-Risk Pulmonary Embolism: Multicenter Registry Study From the Tokyo Cardiovascular Care Unit Network.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yamamoto Takeshi, Yamamoto Hiroyuki, Nozato Toshihiro, Mizuno Atsushi, Hara Nobuhiro, Hisatake Shinji, Asai Kuniya, Kohsaka Shun, Takayama Morimasa
Аннотация
BACKGROUND: High-risk pulmonary embolism (PE) is associated with substantial mortality, and contemporary guidelines recommend prompt reperfusion therapy when feasible. However, real-world data describing how reperfusion is used in practice, and its outcomes, remain limited.
METHODS AND RESULTS: We conducted an observational analysis of patients with high-risk PE enrolled in the Tokyo Cardiovascular Care Unit Network registry between 2020 and 2022. High-risk PE was defined as a presentation complicated with shock, sustained hypotension, or cardiac arrest. Reperfusion therapies included systemic thrombolysis, catheter-based therapy, and surgical embolectomy. Of 1,217 patients with PE, 185 (15.2%) met the high-risk PE criteria. Reperfusion therapy was administered to 43.8% of patients (systemic thrombolysis, 27.6%; surgical embolectomy, 13.0%; catheter-based therapy, 3.2%), and veno-arterial extracorporeal membrane oxygenation (VA-ECMO) was used in 29.7% of patients. Overall, in-hospital mortality was 14.6%. Mortality was lower with than without reperfusion therapy (8.6% vs. 19.2%), without significant differences in bleeding events. In multivariable logistic regression analysis, cardiac arrest, VA-ECMO use, and lack of reperfusion therapy were independently associated with increased in-hospital mortality risk.
CONCLUSIONS: In this contemporary multicenter registry, reperfusion therapy was used in fewer than half of patients with high-risk PE and was associated with lower in-hospital mortality, although residual confounding cannot be excluded given the observational study design. These findings highlight both the potential benefit and the incomplete real-world adoption of guideline-recommended reperfusion strategies.
METHODS AND RESULTS: We conducted an observational analysis of patients with high-risk PE enrolled in the Tokyo Cardiovascular Care Unit Network registry between 2020 and 2022. High-risk PE was defined as a presentation complicated with shock, sustained hypotension, or cardiac arrest. Reperfusion therapies included systemic thrombolysis, catheter-based therapy, and surgical embolectomy. Of 1,217 patients with PE, 185 (15.2%) met the high-risk PE criteria. Reperfusion therapy was administered to 43.8% of patients (systemic thrombolysis, 27.6%; surgical embolectomy, 13.0%; catheter-based therapy, 3.2%), and veno-arterial extracorporeal membrane oxygenation (VA-ECMO) was used in 29.7% of patients. Overall, in-hospital mortality was 14.6%. Mortality was lower with than without reperfusion therapy (8.6% vs. 19.2%), without significant differences in bleeding events. In multivariable logistic regression analysis, cardiac arrest, VA-ECMO use, and lack of reperfusion therapy were independently associated with increased in-hospital mortality risk.
CONCLUSIONS: In this contemporary multicenter registry, reperfusion therapy was used in fewer than half of patients with high-risk PE and was associated with lower in-hospital mortality, although residual confounding cannot be excluded given the observational study design. These findings highlight both the potential benefit and the incomplete real-world adoption of guideline-recommended reperfusion strategies.